Cas:40359-32-8 3-prop-2-enoxybenzaldehyde manufacturer & supplier

We serve Chemical Name:3-prop-2-enoxybenzaldehyde CAS:40359-32-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-prop-2-enoxybenzaldehyde

Chemical Name:3-prop-2-enoxybenzaldehyde
CAS.NO:40359-32-8
Synonyms:3-Allyloxy-benzaldehyd;3-allyloxy-benzaldehyde
Molecular Formula:C10H10O2
Molecular Weight:162.18500
HS Code:2912499000

Physical and Chemical Properties:
Melting point:N/A
Boiling point:273ºC at 760 mmHg
Density:1.058g/cm3
Index of Refraction:1.548
PSA:26.30000
Exact Mass:162.06800
LogP:2.06390

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-Allyloxy-benzaldehyd chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-allyloxy-benzaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Allyloxy-benzaldehyd Use and application,3-allyloxy-benzaldehyde technical grade,usp/ep/jp grade.


Related News: Bluebird determined that death was highly unlikely to have been caused by the delivery virus used in both Zynteglo and LentiGlobin. Benzoic acid, 2-(chloromethyl)- manufacturers Last week, the health ministry estimated the vaccine was only 41% effective at halting symptomatic infections over the past month. Protection against severe disease remained strong at 91%. 4-((R)-((2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl)(3-methoxyphenyl)methyl)-N,N-dibutylbenzamide suppliers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. (S)-7-((4-fluorophenyl)amino)-1-((R)-1-hydroxypropan-2-yl)-3-(4-methoxyphenyl)-4-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one vendor & factory.